Lapatinib plasma and tumor concentrations and effects on HER receptor phosphorylation in tumor

Neil L. Spector, Faith C. Robertson, Sarah Bacus, Kimberly Blackwell, Deborah A. Smith, Kelli Glenn, Leanne Cartee, Jennifer Harris, Carie L. Kimbrough, Mark Gittelman, Eli Avisar, Peter Beitsch, Kevin M. Koch

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Purpose The paradigmshift in cancer treatment from cytotoxic drugs to tumor targeted therapies poses new challenges, including optimization of dose and schedule based on a biologically effective dose, rather than the historicalmaximum tolerated dose. Optimal dosing is currently determined using concentrations of tyrosine kinase inhibitors in plasma as a surrogate for tumor concentrations. To examine this plasma-tumor relationship, we explored the association between lapatinib levels in tumor and plasma in mice and humans, and those effects on phosphorylation of human epidermal growth factor receptors (HER) in human tumors. Experimental Design Mice bearing BT474 HER2+ human breast cancer xenografts were dosed once or twice daily (BID) with lapatinib. Drug concentrations were measured in blood, tumor, liver, and kidney. In a randomized phase I clinical trial, 28 treatment-naïve female patients with early stage HER2+ breast cancer received lapatinib 1000 or 1500 mg once daily (QD) or 500 mg BID before evaluating steady-state lapatinib levels in plasma and tumor. Results In mice, lapatinib levels were 4-fold higher in tumor than blood with a 4-fold longer half-life. Tumor concentrations exceeded the in vitro IC90 (∼ 900 nMor 500 ng/mL) for inhibition of HER2 phosphorylation throughout the 12-hour dosing interval. In patients, tumor levels were 6-and 10-fold higher with QD and BID dosing, respectively, compared to plasma trough levels. The relationship between tumor and plasma concentration was complex, indicating multiple determinants. HER receptor phosphorylation varied depending upon lapatinib tumor concentrations, suggestive of changes in the repertoire of HER homo-and heterodimers. Conclusion Plasma lapatinib concentrations underestimated tumor drug levels, suggesting that optimal dosing should be focused on the site of action to avoid to inappropriate dose escalation. Larger clinical trials are required to determine optimal dose and schedule to achieve tumor concentrations that maximally inhibit HER receptors.

Original languageEnglish (US)
Article numbere0142845
JournalPloS one
Issue number11
StatePublished - Nov 1 2015

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Lapatinib plasma and tumor concentrations and effects on HER receptor phosphorylation in tumor'. Together they form a unique fingerprint.

Cite this